Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Ovid Therapeutics (OVID) Receivables - Other (2020 - 2021)

Ovid Therapeutics' Receivables - Other history spans 2 years, with the latest figure at $1.0 million for Q1 2021.

  • For Q1 2021, Receivables - Other rose 173.56% year-over-year to $1.0 million; the TTM value through Mar 2021 reached $1.0 million, up 173.56%, while the annual FY2020 figure was $141763.0, N/A changed from the prior year.
  • Receivables - Other reached $1.0 million in Q1 2021 per OVID's latest filing, up from $141763.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $1.0 million in Q1 2021 to a low of $141763.0 in Q4 2020.